Allocations
Gulf Capital, a growth markets alternative investment firm, has completed two strategic acquisitions of US healthtech companies for a total transaction value of USD60 million.
The majority stake investments in Eclat Health and Hansei Solutions will expand Gulf Capital’s healthcare-focused Revenue Cycle Management (RCM) platform. In 2018, Gulf Capital had already acquired a majority stake in ACCUMED Practice Management (Accumed), the leading RCM provider in the UAE and Saudi Arabia. Eclat Health (Eclat) is a Washington DC-based technology-enabled healthcare solutions provider, and Hansei Solutions is a tech-driven full-suite RCM operator based out of California.
In line with its buy-and-build strategy
Data in the report ‘Impact investing and the rise of sustainable tech’ shows that impact technology companies are receiving a fast-increasing amount of private equity investment. As the sector matures, those raises are becoming larger and focused on later-stage companies.
GP Bullhound analysed more than 10,000 fundraise transactions and 3,000 M&A transactions, starting in 2015, with the key data insights including:
Record investment levels: Impact companies have raised record levels of investment in Europe and North America in 2020, breaking USD10 billion for the first time
Growing funding rounds: Funding for impact companies has increased by 51 per cent
Vórtx, a tech-enabled corporate and trust service provider for fund managers and corporate issuers in Brazil, has raised USD35 million in Series B funding, led by FTV Capital.
The funding will be used to accelerate Vórtx’s technology enhancements and market presence in the financial back-office market, as the alternatives market in Brazil continues to accelerate.
Vórtx was founded in 2015 by capital markets experts Juliano Cornacchia and Alexandre Assolini, and has since become a one-stop shop for fund managers and corporations alike, through its comprehensive core offering for fund administration and corporate services. Vórtx’s offering includes services in areas
Biomedical startup Adapttech has raised GBP2 million in a new venture capital funding round.
The round was supported by existing investors including the MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia and part of the Midlands Engine Investment Fund; Bionova Capital (formerly Hovione Capital), as well as new investors including ACF Investors, Wealth Club and Wren Capital.
The new funding will be primarily be used for new product developments, and to drive sales of the company’s INSIGHT system, which makes it faster and easier to correctly fit lower-limb prostheses and monitor the rehabilitation process.
Active Capital has sold Active Assurances Groupe, a native digital broker of car and health insurance products, to the Meilleurtaux group after three years of ownership.
Founded in 2011 by Thomas Riottot, Denis Salmoiraghi and Didier Naccache, Active Assurances has enjoyed uninterrupted growth since its launch. The company has quickly established itself as a leading independent online car insurance broker. With management centres in France and Madagascar, the Active Assurances group is set to generate 120,000 new policies during the 2020/2021 financial year (ending in June) and double its turnover.
The acquisition of Active Assurances will enable Meilleurtaux to
Lurra Capital AG, a Swiss-based private capital investment firm, has participated in a USD475 million funding round for New York-headquartered Dataminr, one of the world’s leading AI companies.
Lurra Capital, an existing investor of Dataminr, joins other leading investors including Eldridge, Valor Equity Partners, MSD Capital, Reinvent Capital, ArrowMark Partners, IVP, Eden Global and investment funds managed by Morgan Stanley Tactical Value in providing capital for Dataminr, whose AI platform detects the earliest signs of high-impact events and emerging risks from tracking publicly available data. Clients include Citi, Dyson, Shell and Vodafone.
Founded in 2009 by entrepreneur Ted Bailey,
Fulcrum Equity Partners, a growth equity firm investing in healthcare services, HCIT, B2B SaaS, and tech-enabled services, has closed its fourth and largest fund to date, Fulcrum Growth Fund IV (“Fund IV”), which was oversubscribed with USD275 million in committed capital.
Fulcrum’s existing investor base validated the firm’s thesis and approach with nearly 100 per cent participation from institutional investors in prior funds and many investors increasing their allocations over previous commitments. New institutional investors and family offices also joined the firm’s longtime stable of C-level executives – a key element of Fulcrum’s strategic value-add since its founding in 2006.
“As
In this week’s podcast Private Equity Wire speaks to Sumit Mehta, Managing Director of Arrow Capital, about the growth of SPACs in emerging markets. The podcast looks into the differences between the US ecosystem versus emerging markets and forecasts the challenges that need to be resolved in order to fully leverage the trend globally.
UK start-up LGN has secured USD2 million in funding to help businesses outpace their competition by building better and more resilient AI models, faster and at scale.
With backing from the likes of Trucks Venture Capital, Luminous Ventures and Jaguar Land Rover, LGNenterprises to scale out their use of edge AI and accelerate learning in the real world, rather than in labs and test environments. The company will use the investment to continue its mission of getting AI into the real world. supports
With spending on AI predicted to break the USD500 billion mark by 2024, and more than 50
PhoreMost, a UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable’, disease targets, has completed an oversubscribed GBP33 million (USD46 million) Series B investment round.
The round was led by BGF, the UK’s most active growth economy investor, and included new investors XtalPi Inc, Astellas Venture Management, Trend Investment Group and o2h ventures. Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.
The funding will be used to progress PhoreMost’s preclinical ‘Allosteric PLK1’ collaboration with Sentinel Oncology into the clinic in 2022. The programme is initially targeted towards Glioma. PhoreMost will also progress multiple additional internal first-in-class drug discovery
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
